@article{JGO12109,
author = {Andrew S. Kennedy and David Ball and Steven J. Cohen and Michael Cohn and Douglas M. Coldwell and Alain Drooz and Edward Ehrenwald and Samir Kanani and Fred M. Moeslein and Charles W. Nutting and Samuel G. Putnam III and Steven C. Rose and Michael Savin and Sabine Schirm and Navesh K. Sharma and Eric Wang},
title = {Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {1},
year = {2017},
keywords = {},
abstract = {Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liver-directed radiation, standard laboratory tests may assist in improving outcome by identifying correctable pre-radiation abnormalities.
Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected included background characteristics, prior chemotherapy, surgery/ablation, radiotherapy, vascular procedures, 90Y treatment, subsequent adverse events and survival. Kaplan-Meier estimates compared the survival of patients across lines of chemotherapy. The following values were obtained within 10 days prior to each RE treatment: haemoglobin (HGB), albumin, alkaline phosphatase (Alk phosph), aspartate aminotransferase (AST), alanine transaminase (ALT), total bilirubin and creatinine. Common Terminology Criteria Adverse Events (CTCAEs) 3.0 grade was assigned to each parameter and analysed for impact on survival by line of chemotherapy. Consensus Guidelines were used to categorize the parameter grades as either within or outside guidelines for treatment.
Results: A total of 606 patients (370 male; 236 female) were studied with a median follow-up was 8.5 mo. (IQR 4.3–15.6) after RE. Fewer than 11% of patients were treated outside recommended RE guidelines, with albumin being the most common, 10.5% grade 2 (0 (P0 values are addressed prior to radiation delivery. HGB },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/12109}
}